Compare PK & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PK | IDYA |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.6B |
| IPO Year | 2014 | 2019 |
| Metric | PK | IDYA |
|---|---|---|
| Price | $15.16 | $38.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 16 |
| Target Price | $11.22 | ★ $52.86 |
| AVG Volume (30 Days) | ★ 3.1M | 604.0K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 8.82% | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $2,791,000,000.00 | $218,710,000.00 |
| Revenue This Year | $2.40 | N/A |
| Revenue Next Year | $2.76 | $201.05 |
| P/E Ratio | $51.64 | ★ N/A |
| Revenue Growth | 2.35 | ★ 3024.43 |
| 52 Week Low | $9.84 | $25.36 |
| 52 Week High | $16.20 | $42.68 |
| Indicator | PK | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 47.28 | 52.15 |
| Support Level | $14.28 | $35.11 |
| Resistance Level | $15.48 | $40.58 |
| Average True Range (ATR) | 0.40 | 1.13 |
| MACD | -0.07 | -0.21 |
| Stochastic Oscillator | 41.36 | 36.51 |
Park Hotels & Resorts owns upper-upscale and luxury hotels, with 19,902 rooms across 29 hotels in the United States. Park also has an interest through a joint venture in another 1,424 rooms in another US hotel. Park was spun out of Hilton Worldwide Holdings at the start of 2017, so most of its hotels are still under the Hilton brand. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.